2 completed, 2 terminated, 1 recruiting. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 2, Terminated 2, Recruiting 1 |
Follow Carcinoma, Large Cell: new trials by email Literature Review of Carcinoma, Large Cell trials Research Report on Carcinoma, Large Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel - Carcinoma, Non-Small -Cell Lung | Phase 3 | Recruiting | Maia Biotechnology | 300 | 2025-12-08 | 2026-01-12 |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants Brigatinib, Crizotinib - Non-small Cell Lung Cancer, Lung Cancer | Phase 3 | Completed | Ariad Pharmaceuticals | 275 | 2016-05-26 | 2021-08-20 |
| Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer CP 751,871 (Figitumumab), Erlotinib - Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Pfizer | 583 | 2008-05-01 | 2013-07-24 |
| Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology CP-751,871 (Figitumumab), Carboplatin, Paclitaxel - Carcinoma, Squamous Cell, Carcinoma, Adenosquamous | Phase 3 | Terminated | Pfizer | 681 | 2008-04-01 | 2014-01-13 |
| ZD6474 (ZACTIMAâ„¢) Phase III Study in EGFR Failures ZD6474 (vandetanib), Best Supportive Care - Non-Small-Cell Lung Carcinoma | Phase 3 | Completed | Genzyme, a Sanofi Company | 1140 | 2006-11-01 | 2016-09-30 |
Carcinoma, Non-Small-Cell Lung (5) · Carcinoma, Squamous Cell (5) · Adenocarcinoma (3) · Carcinoma (2) · Carcinoma, Adenosquamous (1) · Lung Neoplasms (1)
Bronchial Neoplasms (5) · Carcinoma, Bronchogenic (5) · Lung Diseases (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Squamous Cell (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Thoracic Neoplasms (5) · Lung Neoplasms (4) · Carcinoma (3) · Neoplasms, Complex and Mixed (1)
figitumumab (2) · Carboplatin (1) · Crizotinib (1) · Docetaxel (1) · Erlotinib Hydrochloride (1) · Gemcitabine (1) · Paclitaxel (1) · Vinorelbine (1) · alpha-2'-deoxythioguanosine (1) · brigatinib (1) · cemiplimab (1) · vandetanib (1)
Pfizer (2) · Ariad Pharmaceuticals (1) · Genzyme, a Sanofi Company (1) · Maia Biotechnology (1)
Taiwan (5) · Canada (4) · France (4) · Italy (4) · South Korea (4) · Spain (4) · United States (4) · Australia (3) · Austria (3) · Germany (3) · Hong Kong (3) · Poland (3) · Switzerland (3) · United Kingdom (3) · Belgium (2)
Victor Zaporojan, Medical Doctor (1)
PMID 24888810, PMID 25395283, PMID 25881079, PMID 28501139, PMID 30280657, PMID 32780660, PMID 38468440, PMID 39707229, PMID 41332393, PMID 41410381, PMID 41740899
2015 (1)